If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

Scribe announced its initial research collaboration with Sanofi for CRISPR-based cell therapies to address oncology ...

Synthego, a leading supplier of CRISPR solutions, has entered a strategic licensing agreement with global biopharmaceutical company AstraZeneca. This agreement grants Synthego a global license to ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Broad coalition of world's greatest thinkers make urgent plea for 'moonshot' efforts to solve 'tragic mismatch of global food <a target=_blank hr ...

Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing ...

ON CRISPR enzyme, will combine with RNA guides for pharma customers. Deal follows HuidaGene agreement, offers 99% cost ...

A study published in Foresight demonstrates that Kognitic's neural network model significantly outperforms traditional methods in predicting primary completion dates (PCD) for clinical trials, ...

Shortly after arriving in Ottawa with her two young children, following her husband's appointment as Cameroon's High Commissioner (Ambassador) to Canada, Mercy Azoh-Mbi complained of fatigue, fever, a ...

An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...